ShiChang Miao, Ph.D.

Dr. Shichang Miao is a seasoned drug developer with 25+ years of experience in drug discovery and development through three biotech companies (Tularik, ChemoCentryx and Amgen). He spent 15 years working at ChemoCentryx, where as VP for preclinical development and clinical pharmacology, he and his team played a pivotal role in the discovery, development and NDA approval of Tavneos™ (avacopan), a complement C5a receptor antagonist indicated for the treatment of a rare autoimmune disease. He has been a partner of Rivermount Fund which specializes in early-stage investment in healthcare startup companies. He has been serving on the advisory committee of the Stanford SPARK Translational Research Program and the Bio Committee of Life Science Angels, a prominent angel investment group focusing on healthcare startups. He has been an active contributor to biotech professional societies, as the founder and president of Pharmaceutical & BioScience Society (PBSS) and a former president (2009-2010) of Chinese American BioPharmaceutical Society (CABS). He obtained his PhD in organic chemistry and postdoctoral training in biochemistry at the University of British Columbia in Vancouver, Canada.